Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
Read Article
News
2024
2023
Archive
Search news articles
January 22, 2013
CETERIX ORTHOPAEDICS COMPLETES $19.5 MILLION SERIES B FINANCING
January 7, 2013
AMBRX APPOINTS LAWSON MACARTNEY, PH.D., DVM, CHIEF EXECUTIVE OFFICER
January 4, 2013
EPIRUS BIOPHARMACEUTICALS, INC. ANNOUNCES POSITIVE PHASE 1 DATA FOR BOW-015
December 17, 2012
FLEXION’S FX006 ACHIEVES PROLONGED THERAPEUTIC CONCENTRATIONS IN JOINTS OF OSTEOARTHRITIS PATIENTS
December 14, 2012
BIOTIE: SELINCRO(TM) (NALMEFENE) RECEIVES POSITIVE OPINION FOR APPROVAL IN THE EUROPEAN UNION
December 11, 2012
BIOTIE’S TOZADENANT (SYN115) MEETS PRIMARY AND MULTIPLE SECONDARY ENDPOINTS IN PHASE 2B STUDY IN PARKINSON’S DISEASE
December 4, 2012
FLEXION THERAPEUTICS SECURES $20 MILLION IN SERIES B FINANCING
November 13, 2012
PEARL THERAPEUTICS RAISES $65 MILLION SERIES D TO START PT003 PHASE 3
November 4, 2012
TAKEDA TO ACQUIRE ENVOY THERAPEUTICS, INC.
October 11, 2012
C. ROBERT KIDDER JOINS BOARD OF DIRECTORS OF WILDCAT DISCOVERY TECHNOLOGIES, INC.
« Previous Page
1
…
104
105
106
107
108
…
118
Next Page »